SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid with Merck’s subsidiary achieves milestone in anti-infectives research

20 Dec 2011 Evaluate

Orchid Chemicals & Pharmaceuticals (Orchid) has successfully achieved a milestone in its anti-infectives research in collaboration with a subsidiary of Merck & Company, Inc (Merck). Consequent to recent progress, Orchid has received the initial $1.5 million milestone payment from Merck.

Under the terms of the agreement, Orchid is eligible to receive payments totaling more than $100 million associated with the achievement of various research and development milestones involving multiple candidates. Further, the company is also eligible to receive significant royalties on worldwide net sales of any products commercialized under the agreement.

The two companies announced a collaborative research agreement in September 2008, with focus on the discovery, development and commercialization of novel agents for the treatment of bacterial and fungal infections for which Orchid received an upfront payment.

Orchid's drug discovery efforts are conducted through its wholly-owned subsidiary, Orchid Research Laboratories.

Orchid is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×